Assessing Furmonertinib for Non-small Cell Lung Cancer After Surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 3, double-blind, randomized, placebo-controlled trial evaluates the efficacy and safety of Furmonertinib in patients with stage II-IIIA non-small cell lung carcinoma (NSCLC) who have undergone complete tumor resection. Participants must have confirmed EGFR mutations associated with sensitivity to EGFR-TKI therapy. The study aims to determine if Furmonertinib can improve outcomes compared to a placebo in this patient population. Patients will be monitored for safety and efficacy following treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female, aged at least 18 years.
* Histologically confirmed diagnosis of primary non-small lung cancer (NSCLC) on predominantly non-squamous histology.
* MRI or CT scan of the brain must be done prior to surgery as it is considered standard of care.
* Patients must be classified post-operatively as Stage IB, II, or IIIA on the basis of pathologic criteria.
* Confirmation by the central laboratory that the tumor harbors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.
* Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for the tumor.
* Complete recovery from surgery and standard post-operative therapy (if applicable) at the time of randomization.
* World Health Organization Performance Status of 0 to 1.
* Female patients should be using adequate contraceptive measures, should not be breastfeeding, and must have a negative pregnancy test prior to the first dose of the study drug; or female patients must have evidence of non-child-bearing potential.

Exclusion Criteria:

* Pre-operative or post-operative or planned radiation therapy for the current lung cancer
* Pre-operative (neo-adjuvant) platinum-based or other chemotherapy
* Any prior anticancer therapy
* Prior treatment with neoadjuvant or adjuvant EGFR-TKI at any time
* Major surgery (including primary tumor surgery, excluding placement of vascular access) within 4 weeks of the first dose of study drug
* Patients currently receiving medications or herbal supplements known to be potent inducers of cytochrome P450 (CYP) 3A4
* Treatment with an investigational drug within five half-lives of the compound or any of its related material.
* Patients who have had only segmentectomies or wedge resections
* History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumors curatively treated with no evidence of disease for \> 5 years following the end of treatment.
* Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.
* Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV).
* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9291.
* Any of the following cardiac criteria:
* Mean resting corrected QT interval (QTc) \>470 msec, obtained from 3 ECGs, using the screening clinic ECG Machine-derived QTc value.
* Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG.
* Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval.
* Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
* Inadequate bone marrow reserve or organ function.

Where it's running

• First Affiliated Hospital of Soochow University
  Suzhou, Jiangsu, China Recruiting

Study contacts

• Principal investigator: Jianxing He, PHD — The First Affiliated Hospital of Guangzhou Medical University
• Study coordinator: Jianxing He, PHD
• Email: drjianxing.he@gmail.com
• Phone: 020-83062114

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vebreltinib plus furmonertinib in EGFR-mutated NSCLC with high PD-L1

  This study tests whether combining vebreltinib with furmonertinib can help people with advanced NSCLC that has EGFR mutations and very high PD-L1 expression.

  Recruiting Phase 1/2 Second Affiliated Hospital of Nanchang University · Nanchang, Jianxi · NCT07655622

• Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

  This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.

  Recruiting at 11 sites Groupe Francais De Pneumo-Cancerologie · Aix-en-Provence and 15 other locations · NCT07563205

• Sacituzumab tirumotecan plus furmonertinib for advanced EGFR‑mutant non‑squamous lung cancer after EGFR‑TKI and platinum chemotherapy

  This Phase II trial will test whether combining sacituzumab tirumotecan with furmonertinib helps people with advanced EGFR‑mutant non‑squamous NSCLC who progressed after EGFR‑TKI and platinum chemotherapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07548060

• Pulsatile high-dose furmonertinib for EGFR-mutant NSCLC with leptomeningeal metastasis

  This tests whether taking high-dose furmonertinib every other day helps people with EGFR-mutant non-small cell lung cancer that has spread to the leptomeninges.

  Recruiting Guangzhou University of Traditional Chinese Medicine · Guangzhou, Guangdong · NCT07348965

• Furmonertinib plus intrathecal chemotherapy and stereotactic radiotherapy for EGFR‑mutated NSCLC with brain parenchymal and leptomeningeal metastases

  This trial tries to see if taking furmonertinib with spinal‑fluid chemotherapy injections and focused brain radiotherapy helps people with EGFR‑mutated lung cancer who have both brain and leptomeningeal metastases.

  Recruiting at 3 sites Phase 2 Tianjin Medical University Cancer Institute and Hospital · Cangzhou, Hebei and 2 other locations · NCT07304739

• PLX-61639 for advanced SMARCA4-deficient solid tumors

  This trial will test a daily oral drug called PLX-61639 in people with advanced or metastatic solid tumors that have a SMARCA4 loss and who have no other approved treatment options.

  Recruiting at 10 sites Phase 1 Plexium, Inc. · Scottsdale, Arizona and 9 other locations · NCT07284186

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.